Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Candesartan32mg
Amlodipine10mg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Pharmacokinetics, Safety, Male
Eligibility Criteria
Inclusion Criteria:
- Healthy male, Age 20 to 45
- Subject must be willing and able to provide written informed consent to the study.
Exclusion Criteria:
- History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
- History of any significant gastrointestinal system and surgery of gastrointestinal.
- History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.
- Over 10 tobaccos a day.
- Other condition which in the opinion of the investigator preclude endrollment into the study.
Sites / Locations
- Chungnam national university hospital,clinical trial center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
PartA: Candesartan, Candesartan + Amolodipine
PartB: Amlodipine, Amlodipine+Candesartan
Arm Description
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
Outcomes
Primary Outcome Measures
Part A : AUC, Cmax of Candesartan
Par B : AUC, Cmax of Amlodipine
Secondary Outcome Measures
PartA: Cmin, tmax, CL/F of Candesartan
PartB: Cmin, tmax, CL/F of Amlodipine
Full Information
NCT ID
NCT01806311
First Posted
March 4, 2013
Last Updated
February 24, 2014
Sponsor
HanAll BioPharma Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT01806311
Brief Title
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
Official Title
An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HanAll BioPharma Co., Ltd.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Pharmacokinetics, Safety, Male
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
34 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PartA: Candesartan, Candesartan + Amolodipine
Arm Type
Active Comparator
Arm Description
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
Arm Title
PartB: Amlodipine, Amlodipine+Candesartan
Arm Type
Active Comparator
Arm Description
Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
Intervention Type
Drug
Intervention Name(s)
Candesartan32mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine10mg
Primary Outcome Measure Information:
Title
Part A : AUC, Cmax of Candesartan
Time Frame
Over a 24-hour sampling period
Title
Par B : AUC, Cmax of Amlodipine
Time Frame
Over a 24-hour sampling period
Secondary Outcome Measure Information:
Title
PartA: Cmin, tmax, CL/F of Candesartan
Time Frame
Over a 24-hour sampling period
Title
PartB: Cmin, tmax, CL/F of Amlodipine
Time Frame
Over a 24-hour sampling period
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male, Age 20 to 45
Subject must be willing and able to provide written informed consent to the study.
Exclusion Criteria:
History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
History of any significant gastrointestinal system and surgery of gastrointestinal.
History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.
Over 10 tobaccos a day.
Other condition which in the opinion of the investigator preclude endrollment into the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jang Hee Hong, Associate Professor
Organizational Affiliation
Chungnam national university hospital, Clinical trial center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chungnam national university hospital,clinical trial center
City
Daejeon
State/Province
Chungcheongbul-do
ZIP/Postal Code
301-721
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
We'll reach out to this number within 24 hrs